$31.79
+11%Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
Moderate margins typical of competitive industries. Monitor for pricing pressure or rising costs.
Acceptable margins but limited operational leverage. Operating expense control is important.
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
PAHC โข NASDAQ
| Phibro Animal Health Corporation Income Statement | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | Jun 2007 | Jun 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
1.3B | 1B | 977.9M | 942.3M | 833.4M | 800.4M | 828M | 820M | 764.3M | 751.5M | 748.6M | 691.9M | 653.2M | 654.1M | 618.3M | 594.2M | 537.1M | 511.4M | 453M | 398.4M | |
GROSS PROFIT | ||||||||||||||||||||
(896.3M) | (704.6M) | (679.7M) | (656.9M) | (562M) | (543.5M) | (563.4M) | (553.1M) | (516M) | (512.5M) | (512.2M) | (484.1M) | (474.2M) | (490M) | (471.7M) | (439.5M) | (407.5M) | (389.7M) | (341.8M) | (307.3M) | |
399.9M | 313.1M | 298.2M | 285.4M | 271.4M | 256.9M | 264.6M | 266.9M | 248.3M | 239M | 236.4M | 207.8M | 179M | 164.1M | 146.7M | 154.7M | 129.6M | 121.7M | 111.2M | 91.1M | |
OPERATING INCOME | ||||||||||||||||||||
(289.5M) | (259.8M) | (226.4M) | (206.4M) | (196.5M) | (187.7M) | (181.4M) | (168M) | (150.3M) | (153.3M) | (148.7M) | (144M) | (122.2M) | (114.8M) | (105.4M) | (101.9M) | (88.2M) | (92.4M) | (90.2M) | (68.1M) | |
(289.5M) | (259.8M) | (226.4M) | (206.4M) | (196.5M) | (187.7M) | (181.4M) | (168M) | (150.3M) | (153.3M) | (148.7M) | (144M) | (122.2M) | (114.8M) | (105.4M) | (101.9M) | (84.6M) | (81.3M) | (76.2M) | (68.1M) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (12.1M) | (10M) | (9.4M) | (11M) | (9.5M) | (8.2M) | (6.6M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
110.5M | 53.3M | 71.8M | 79M | 74.9M | 69.2M | 73.3M | 98.9M | 97.9M | 85.7M | 87.7M | 63.8M | 56.7M | 49.3M | 41.2M | 52.8M | 41.4M | 29.3M | 21.1M | 23M | |
PRE-TAX INCOME | ||||||||||||||||||||
(33.2M) | (22M) | (17.9M) | (12.1M) | (10.4M) | (14.3M) | (13.7M) | (13.6M) | (16.9M) | (16.8M) | (14.6M) | (33M) | (35.8M) | (35.7M) | (34.6M) | -33.1M | -43.4M | -26.9M | -27.3M | -32.6M | |
-30.6M | -17.5M | -14.6M | -11.3M | -9.6M | -12.5M | -11.8M | -11.9M | -14.9M | -16.6M | -14.3M | -33M | -35.6M | -35.4M | -34.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -151K | (400K) | -593K | (0.0) | (3.6M) | (11.1M) | (14M) | (0.0) | |
-42.5M | -42.4M | -17.8M | -6.7M | -8.4M | -13.7M | -11.7M | -10.9M | -17.4M | -19.4M | -8.9M | -57.5M | -38.9M | -36.2M | -49.1M | -33.2M | -43.5M | -27.4M | -27.4M | -30.9M | |
68M | 10.9M | 54.1M | 72.3M | 66.5M | 55.5M | 71.5M | 88.1M | 80.5M | 76.8M | 78.8M | 6.3M | 17.8M | 13.1M | -7.9M | 19.6M | -2.1M | 1.9M | -6.3M | -7.9M | |
NET INCOME | ||||||||||||||||||||
(19.7M) | (8.5M) | (21.5M) | (23.2M) | (12.1M) | (22M) | (16.8M) | (23.2M) | (15.9M) | -6M | (18.5M) | (9.4M) | -7M | (6.1M) | (5M) | (3.8M) | (3.4M) | (2.6M) | (400K) | (5.2M) | |
48.3M | 2.4M | 32.6M | 49.2M | 54.4M | 33.6M | 54.7M | 64.9M | 64.6M | 82.7M | 60.3M | -3.1M | 24.9M | 7M | -12.9M | 42.1M | -8.3M | 2.2M | -6.7M | -13.1M |
PAHC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 14, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 04, 2026 | February 04, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 03, 2026 | February 03, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 16, 2025 | 2025 |
Continue your PAHC research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.